Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
New Biological and Immunological Approaches to Cancer Therapy
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

New Biological and Immunological Approaches to Cancer Therapy

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (28 January 2024) | Viewed by 2694

Special Issue Editor

Prof. Dr. Andrea Nicolini

E-Mail Website
Guest Editor
Department of Internal Medicine, University of Pisa, Santa Chiara Hospital, via Roma 67, 56126 Pisa, Italy
Interests: breast and gastrointestinal cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

In the last two decades, most research in cancer focused on the comprehension of the genetic and molecular biology mechanisms accounting for and joining with its evolution. Cancer cell spread to distant organs and the common occurrence of resistance to therapy are key cancer features responsible for the high lethality of the disease. A better understanding of the main mechanisms underpinning these procedures fosters our expectation for a substantial improvement of cancer patients’ prognosis. At the same time, many researches have without any doubt proven the relevant role that cellular immunity plays in cancer progression and diffusion in addition to that it plays in cancer origin. Particularly, in more recent years, much research has highlighted the immune suppressive microenvironment favoring tumor growth. Following this, novel immunotherapeutic strategies given alone or combined with hormone therapy or chemotherapy have been proposed and successfully evaluated in clinical trials. The principal aim of this Special Issue is to favor original research and new ideas that can expand the knowledge on these subjects.

Prof. Dr. Andrea Nicolini
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • cancer molecular biology
  • cancer immunology
  • cancer immunotherapy
  • new cancer therapies

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 2135 KiB  
Article
A New Opportunity for “Old” Molecules: Targeting PARP1 Activity through a Non-Enzymatic Mechanism
by Pablo Iglesias, Marcos Seoane, Irene Golán-Cancela, Máximo Fraga, Victor M. Arce and Jose A. Costoya
Int. J. Mol. Sci. 2023, 24(10), 8849; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms24108849 - 16 May 2023
Viewed by 1290
Abstract
In recent years, new therapies have been developed based on molecules that target molecular mechanisms involved in both the initiation and maintenance of the oncogenic process. Among these molecules are the poly(ADP-ribose) polymerase 1 (PARP1) inhibitors. PARP1 has emerged as a target with [...] Read more.
In recent years, new therapies have been developed based on molecules that target molecular mechanisms involved in both the initiation and maintenance of the oncogenic process. Among these molecules are the poly(ADP-ribose) polymerase 1 (PARP1) inhibitors. PARP1 has emerged as a target with great therapeutic potential for some tumor types, drawing attention to this enzyme and resulting in many small molecule inhibitors of its enzymatic activity. Therefore, many PARP inhibitors are currently in clinical trials for the treatment of homologous recombination (HR)-deficient tumors, BRCA-related cancers, taking advantage of synthetic lethality. In addition, several novel cellular functions unrelated to its role in DNA repair have been described, including post-translational modification of transcription factors, or acting through protein–protein interactions as a co-activator or co-repressor of transcription. Previously, we reported that this enzyme may play a key role as a transcriptional co-activator of an important component of cell cycle regulation, the transcription factor E2F1. Here, we show that PARP inhibitors, which interfere with its activity in cell cycle regulation, perform this without affecting its enzymatic function. Full article
(This article belongs to the Special Issue New Biological and Immunological Approaches to Cancer Therapy)
►▼ Show Figures

Figure 1

Review

Jump to: Research

18 pages, 2099 KiB  
Review
T Cell Receptor Chain Centricity: The Phenomenon and Potential Applications in Cancer Immunotherapy
by Anastasiia A. Kalinina, Ludmila M. Khromykh and Dmitry B. Kazansky
Int. J. Mol. Sci. 2023, 24(20), 15211; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms242015211 - 16 Oct 2023
Viewed by 1032
Abstract
T cells are crucial players in adaptive anti-cancer immunity. The gene modification of T cells with tumor antigen-specific T cell receptors (TCRs) was a milestone in personalized cancer immunotherapy. TCR is a heterodimer (either α/β or γ/δ) able to recognize a peptide antigen [...] Read more.
T cells are crucial players in adaptive anti-cancer immunity. The gene modification of T cells with tumor antigen-specific T cell receptors (TCRs) was a milestone in personalized cancer immunotherapy. TCR is a heterodimer (either α/β or γ/δ) able to recognize a peptide antigen in a complex with self-MHC molecules. Although traditional concepts assume that an α- and β-chain contribute equally to antigen recognition, mounting data reveal that certain receptors possess chain centricity, i.e., one hemi-chain TCR dominates antigen recognition and dictates its specificity. Chain-centric TCRs are currently poorly understood in terms of their origin and the functional T cell subsets that express them. In addition, the ratio of α- and β-chain-centric TCRs, as well as the exact proportion of chain-centric TCRs in the native repertoire, is generally still unknown today. In this review, we provide a retrospective analysis of studies that evidence chain-centric TCRs, propose patterns of their generation, and discuss the potential applications of such receptors in T cell gene modification for adoptive cancer immunotherapy. Full article
(This article belongs to the Special Issue New Biological and Immunological Approaches to Cancer Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop